Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs

2010 ◽  
Vol 10 (1) ◽  
pp. 81-88 ◽  
Author(s):  
Philipp Harter ◽  
Felix Hilpert ◽  
Sven Mahner ◽  
Florian Heitz ◽  
Jacobus Pfisterer ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Systemic Therapy ◽  
Treatment Options ◽  
Recurrent Ovarian Cancer ◽  
Current Treatment ◽  
New Drugs

Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review

2019 ◽  
Vol 152 (2) ◽  
pp. 416-425 ◽  
Author(s):  
Mary M. Mullen ◽  
Lindsay M. Kuroki ◽  
Premal H. Thaker
Keyword(s):  
Ovarian Cancer ◽  
Treatment Options ◽  
Recurrent Ovarian Cancer ◽  
Platinum Sensitive ◽  
Novel Treatment

scholarly journals Targeting the Serine Pathway: A Promising Approach against Tuberculosis?

2019 ◽  
Vol 12 (2) ◽  
pp. 66 ◽  
Author(s):  
Marie Haufroid ◽  
Johan Wouters
Keyword(s):  
Treatment Options ◽  
Infectious Agent ◽  
Selective Inhibition ◽  
Current Treatment ◽  
New Drugs ◽  
Therapeutic Drug ◽  
Regulatory Domains ◽  
Starting Point ◽  
Drug Discovery Program ◽  
Serine Pathway

Tuberculosis is still the leading cause of death by a single infectious agent. Effective chemotherapy has been used and improved since the 1950s, but strains resistant to this therapy and most antibacterial drugs on the market are emerging. Only 10 new drugs are in clinical trials, and two of them have already demonstrated resistance. This paper gives an overview of current treatment options against tuberculosis and points out a promising approach of discovering new effective drugs. The serine production pathway is composed of three enzymes (SerA1, SerC and SerB2), which are considered essential for bacterial growth, and all of them are considered as a therapeutic drug target. Their crystal structure are described and essential regulatory domains pointed out. Sequence alignment with similar enzymes in other host would help to identify key residues to target in order to achieve selective inhibition. Currently, only inhibitors of SerB2 are described in the literature. However, inhibitors of human enzymes are discussed, and could be used as a good starting point for a drug discovery program. The aim of this paper is to give some guidance for the design of new hits for every enzyme in this pathway.

scholarly journals Advances in systemic therapy for advanced pancreatobiliary malignancies

F1000Research ◽  
2013 ◽  
Vol 2 ◽  
pp. 105
Author(s):  
Thorvardur R Halfdanarson ◽  
Sigurdis Haraldsdottir ◽  
Mitesh J Borad
Keyword(s):  
Radiation Therapy ◽  
Systemic Therapy ◽  
Patient Survival ◽  
Advanced Disease ◽  
Treatment Options ◽  
Locally Advanced ◽  
Current Treatment ◽  
Targeted Treatments ◽  
Poor Treatment ◽  
Novel Approaches

Pancreatobiliary malignancies are relatively uncommon and the overall prognosis is poor. Treatment options for advanced disease are limited to systemic therapy for metastatic disease and a combination of systemic therapy and radiation therapy for locally advanced but unresectable tumors. There have been significant advances in the treatment of pancreatobiliary cancers in recent years but the prognosis for patient survival remains disappointingly poor. We review the current treatment options for locally advanced pancreatobiliary malignancies and highlight recent advances in systemic therapy, including novel approaches using targeted treatments.

scholarly journals Do all patients with recurrent ovarian cancer need systemic therapy?

Cancer ◽  
2019 ◽  
Vol 125 (S24) ◽  
pp. 4602-4608
Author(s):  
Michael L. Friedlander
Keyword(s):  
Ovarian Cancer ◽  
Systemic Therapy ◽  
Recurrent Ovarian Cancer

Management of Prostate Cancer with Systemic Therapy. A Prostate Cancer Unit Perspective

2020 ◽  
Vol 20 ◽  
Author(s):  
Fabio Campodonico ◽  
Marco Ennas ◽  
Silvia Zanardi ◽  
Ekaterini Zigoura ◽  
Arnoldo Piccardo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systemic Therapy ◽  
Treatment Options ◽  
New Drugs ◽  
Group Discussions ◽  
New Agents ◽  
Target Imaging ◽  
Multidisciplinary Group ◽  
Points Of View ◽  
New Treatment

: The scenario of systemic therapy for prostate cancer is rapidly evolving, with new drugs and new treatment options. To update the background knowledge of shared uro-oncologic practice, we reviewed current statements and landmarks in systemic therapy. A number of new agents are under investigation in non-metastatic and metastatic disease. Similarly, new target imaging technologies are under development to improve the detection rate of true non-metastatic and true metastatic patient. Five new drugs have shown to be effective on progression-free and overall survival in metastatìc prostate cancer. However, the optimal sequencing of these treatments requires further investigations. The tolerability and side effects of the new drugs are also crucial issues to be discussed, as well as their activity against the disease. The uro-oncologic team has to stay updated about new medical therapies in order to be confident in debating with other professionals involved in prostate cancer decision making. Different points of view and nuances should be shared during multidisciplinary group discussions to achieve a balanced decision in the disease management.

A phase II trial of combination irinotecan and oral etoposide chemotherapy in recurrent ovarian cancer: A Tohoku Gynecologic Cancer Unit (TGCU) study

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 5558-5558
Author(s):  
S. Kumagai ◽  
T. Shoji ◽  
Y. Yokoyama ◽  
T. Takano ◽  
H. Mizunuma ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Treatment Options ◽  
Gynecologic Cancer ◽  
Progression Free Survival ◽  
Recurrent Ovarian Cancer ◽  
Median Number ◽  
Oral Etoposide ◽  
Eligibility Criteria ◽  
Platinum Resistant

5558 Background: Various problems still exist in the management of recurrent ovarian cancer and there are limited treatment options especially for the platinum resistant patients (pts). We conducted a phase II study to evaluate the efficacy and safety of the combination irinotecan/oral etoposide chemotherapy. Methods: Eligibility criteria included recurrent ovarian cancer with measurable disease or positive CA125, preserved organ function, and aged 20–75. Treatment was conducted with irinotecan (60 mg/m2 iv, day 1, 15) and oral etoposide (50 mg/body day 1–21), q 28 days until disease progression or unacceptable toxicity. Primary endpoint was response rate (RR) and secondary endpoints included toxicity, progression-free survival (PFS), and overall survival (OS). Results: 38pts were enrolled on this study from May 2003 to April 2007, and all pts were eligible. Median age was 57 yrs (range 37–74). PS 0 in 24 pts, 1 in 10 pts, and 2 in 4 pts. Median number of previous regimen was 2 (range 1–4). Median treatment cycles were 6 (range 2–27). RR (CR+PR) was 18/38 (47.4%), and CR+PR+SD rate was 31/38 (81.6%). Grade 3/4 adverse effect included leukopenia (50.0%), neutropenia (52.6%), anemia (18.4%) and thrombocytopenia (2.6%), nausea/vomiting (7.9%) and diarrhea (2.6%). Treatment-related death was not observed. Median PFS was 7 months (range 1–33) and OS was 19 months (range 4–60). Among 20 pts with platinum resistant cases, RR was 6/20 (30.0%), CR+PR+SD rate was 14/20 (70.0%), median PFS was 6 months (range 1–33), and OS was 24 months (range 5–60). Conclusions: Combination irinotecan/oral etoposide chemotherapy can achieve a superior management for the recurrent ovarian cancer without declining QOL, and also has the possibility to be one of the most effective regimens as second-line chemotherapy. No significant financial relationships to disclose.

Effects of weekly bevacizumab and pegylated liposomal doxorubicin in heavily pretreated patients with recurrent or progressed ovarian cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 5547-5547
Author(s):  
Y. Kikuchi ◽  
H. Kouta ◽  
R. Kikuchi ◽  
M. Takano ◽  
T. Kita ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Liposomal Doxorubicin ◽  
Treatment Options ◽  
Evaluation Criteria ◽  
Pegylated Liposomal Doxorubicin ◽  
Recurrent Ovarian Cancer ◽  
Cytotoxic Agents ◽  
Ca 125 ◽  
Heavily Pretreated ◽  
Pretreated Patients

5547 Background: Vascular endothelial growth factor (VEGF) plays a central role in tumor angiogenesis and is regarded a promising therapeutic target. Bevacizumab (A) has significant antitumor activity in combination with cytotoxic agents. Currently, pegylated liposomal doxorubicin (D) is provided as one of the standard treatment options in recurrent ovarian cancer. Thus, we attempted to determine effects in combination of A and D for heavily pretreated patients with recurrent or progressed ovarian cancer. Methods: Twenty-two patients with heavily pretreated (more than one regimen or more than 6 cycles by paclitaxerl and carboplatin) received at least more than 3 cycles of weekly A-D consisting of A: 2 mg/kg and D: 10 mg/m2 (3 weeks, one week rest). The primary endpoint was response according to CA 125 and response evaluation criteria in solid tumor (RECIST) criteria. Results: Of 22 patients evaluable for CA 125 response, 7 (32%) had a response (decrease of >50%), and 8 (36%) patients had not progressed (doubling of CA 125) following 6 months on treatment. In RECIST evaluation, 2 (9%) patients had complete remission (CR) and 6 (27%) had partial remission (PR), resulting in 55% clinical benefit rate (CBR). Progression free interval (PFI) showed more than 6 months. Any hematological adverse effect was not observed in the present study. Gastrointestinal perforation was observed in only one case and was conservatively treated. Although nasal bleeding was frequently observed, no treatment was required. A induced hypertension was also observed and manageable. Hand-foot syndrome seemed due to D was seen in 3 of 22 patients and treatment was required in only one case. Conclusions: B seemed to enhance effect of D. This is the first study of weekly A-D in heavily pretreated ovarian cancer patients. Weekly A-D warrants further clinical study in such clinical settings. No significant financial relationships to disclose.

Expression III: What do primary and recurrent ovarian cancer (OC) patients expect from their doctors and therapy management? Results of a survey in eight European countries with 1,743 patients (NOGGO/ENGOT-OV9 study).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 5569-5569 ◽  
Author(s):  
Gülten Oskay-Özcelik ◽  
Maren Keller ◽  
Sandro Pignata ◽  
Domenica Lorusso ◽  
Florence Joly ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Side Effects ◽  
Cancer Patients ◽  
Information Needs ◽  
Treatment Options ◽  
Recurrent Ovarian Cancer ◽  
European Countries ◽  
Second Opinion ◽  
Cancer Therapies ◽  
Therapy Management

5569 Background: The primary aim of this study was to investigate information needs and preferences among patients with ovarian cancer, focusing especially on doctor-patient relationships and therapy management in different European countries. Methods: A questionnaire was developed based on the experiences of expression II, a German survey, and then provided to primary and recurrent ovarian cancer patients via internet (online) or as a print-version in 8 countries in Europe (Austria, Belgium, France, Germany, Italy, Poland, Rumania, Spain). In the first part basic data (age, tumour status, therapy) were requested from the patient. In the second part, most of the questions tried to evaluate the expectations and needs concerning their therapy management and doctor-patient communication. Results: From December 2009 to October 2012, a total of 1743 patients with ovarian cancer from 8 European countries participated in the survey.The median age was 58 years (range 16-89). Nearly all patients (96,3%) had a primary surgery and a first-line chemotherapy (91,5%). About 423 (25,7%) patients were included in another clinical trial.Most of the patients in each country were pleased with the completeness and understandability of the explanations about the therapies from their doctors. About 68% of patients would be interested in having the opportunity to have a second opinion. The three most important aspects, which were proposed by patients to improve therapy against ovarian cancer were: “the therapy should not induce alopecia” (42%), “there must be more done to counter fatigue” (34%), and “the therapy should be more effective” (29%). Conclusions: This study underlines the high need of ovarian cancer patients to discuss all details concerning treatment options and clinical management with only minor difference between the countries. Patients also need more information about side effects of cancer therapies and second opinion opportunities. Besides effectiveness of therapy, alopecia and fatigue are the most important side effects bothering the patients.

What Are the Treatment Options for Recurrent Ovarian Cancer?

2013 ◽  
pp. 101-110
Author(s):  
Jonathan A. Ledermann ◽  
Fharat A. Raja ◽  
Philipp Harter ◽  
Florian Heitz
Keyword(s):  
Ovarian Cancer ◽  
Treatment Options ◽  
Recurrent Ovarian Cancer
Sign in / Sign up

Export Citation Format

Share Document